Showing results (61-70 of 108) with videos related to
Sort By:
Pageof 11
JTO Clinical and Research Reports|January 31, 2023
Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous NSCLCZoran Andric, Gabriella Gálffy, Manuel Cobo Dols, et al.JCO Precision Oncology|May 30, 2024
Impact of Clonal Hematopoiesis-Associated Mutations in Phase I Patients Treated for Solid Tumors: An Analysis of the STING TrialJulieta Rodriguez, Capucine Baldini, Arnaud Bayle, et al.The Lancet. Oncology|October 9, 2019
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trialKazuhiko Nakagawa, Edward B Garon, Takashi Seto, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2024
Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced <i>EGFR</i>-Mutant Non-Small-Cell Lung CancerJordi Remon, Benjamin Besse, Santiago Ponce Aix, et al.Current Oncology Reports|July 27, 2024
Exploring the Role of Target Expression in Treatment Efficacy of Antibody-Drug Conjugates (ADCs) in Solid Cancers: A Comprehensive ReviewLaurent Mathiot, Capucine Baldini, Octave Letissier, et al.European Journal of Cancer (Oxford, England : 1990)|July 10, 2022
Nazartinib for treatment-naive EGFR-mutant non-small cell lung cancer: Results of a phase 2, single-arm, open-label studyDaniel S W Tan, Sang-We Kim, Santiago Ponce Aix, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 2, 2024
RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLCKazuhiko Nakagawa, Edward B Garon, Takashi Seto, et al.Cancer Discovery|June 28, 2023
Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial CancerFrancesco Facchinetti, Antoine Hollebecque, Floriane Braye, et al.Cancer Biology & Medicine|June 27, 2020
Clinical-pathological and molecular characterization of long-term survivors with advanced non-small cell lung cancerJuan Moreno-Rubio, Santiago Ponce, Rosa Álvarez, et al.Lung Cancer (Amsterdam, Netherlands)|February 29, 2024
Blood tumor mutational burden and response to pembrolizumab plus chemotherapy in non-small cell lung cancer: KEYNOTE-782Jair Bar, Emilio Esteban, Delvys Rodríguez-Abreu, et al.Pageof 11